CurrentNeighborhood Health Plan of Rhode IslandPolicy 1959-A

Actemra

Outpatient coverage policy for Actemra (tocilizumab) and listed biosimilars across FDA-approved indications and selected compendial uses, with prior authorization documentation, prescriber specialty requirements, dosing limits per labeling, and continuation criteria. Hospitalized COVID-19 management is excluded from this outpatient policy.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyActemra

Policy CodePolicy 1959-A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization with required documentation (chart notes, medical records, claims history, biomarker/imaging results, and TB screening) demonstrating indication-specific criteria and prior therapies tried and response.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes.

7FDA-approved Indications Listed

9Compendial/Other Indications Listed

12Authorization Durations (months) Mentioned

Coverage Summary

This outpatient policy (policy_number 1959-A; subject: Actemra (tocilizumab) and biosimilars coverage) addresses coverage for tocilizumab (Actemra) and the listed biosimilars (Avtozma, Tofidence, Tyenne) across FDA‑approved indications and selected compendial uses when approval criteria are met. Prior authorization with supporting documentation is required, prescribing must be by or in consultation with the specified specialty per indication, and approvals are subject to dosing limits per FDA labeling/accepted compendia. Management of hospitalized patients with COVID‑19 (including those receiving systemic corticosteroids and requiring supplemental oxygen, ventilatory support, or ECMO) is excluded from this outpatient policy and is handled under inpatient benefits.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Drug products covered (brand and biosimilars)NDC|HCPCS|mixedCovered

Actemra	tocilizumab (brand)
Avtozma	tocilizumab-anoh (biosimilar)
Tofidence	tocilizumab-bavi (biosimilar)
Tyenne	tocilizumab-aazq (biosimilar)

Initial Therapy Criteria

Coverage — General

Covered when ALL of the following are met:

ALL of the following

General coverage requirements
- Requested product: Requested drug is Actemra (tocilizumab) or listed biosimilar (Avtozma, Tofidence, Tyenne).
- Indication is one of the listed FDA-approved or compendial uses.
- Exclusions: Member has no exclusions to the prescribed therapy (e.g., active tuberculosis).
- Prescriber specialty: Prescriber is within required specialty or in consultation with required specialty per indication (see Prescriber Specialties).

Coverage — General (summary): Policy requires prior authorization and documentation that the requested product, indication, absence of exclusions, and prescriber specialty/consultation requirements are met.

FDA-Approved Indications — Initial Authorization Criteria

Authorization may be granted when ALL of the following specific indication-based criteria are met (duration varies by indication):

Applicable FDA-approved indications

Rheumatoid arthritis (RA) — adults: Moderately to severely active RA in adults; inadequate response to one or more DMARDs; biomarker testing: either RF or anti-CCP positive OR tested for RF, anti-CCP, and CRP and/or ESR. Authorization of 12 months may be granted for adults who previously received a biologic or targeted synthetic DMARD.
Authorization of 12 months may be granted
Polyarticular juvenile idiopathic arthritis (pJIA) — age ≥2: Active pJIA in members ≥2 years of age. Authorization of 12 months may be granted for members who have previously received a biologic or targeted synthetic drug indicated for active articular JIA.
Authorization of 12 months may be granted
Systemic juvenile idiopathic arthritis (sJIA) — age ≥2: Active sJIA in members ≥2 years of age with active systemic features; authorization of 12 months may be granted for members who previously received a biologic indicated for active sJIA.

Compendial Uses — Initial Authorization Criteria

Authorization for selected compendial uses may be granted when the listed criteria are met:

Compendial Uses (initial)

Unicentric Castleman disease: Member is HIV-negative; human herpesvirus-8-negative; requested medication will be used as a single agent; disease has progressed following treatment of relapsed/refractory disease or is surgically unresectable. Authorization of 12 months may be granted.
Authorization of 12 months may be granted
Multicentric Castleman disease: Either: (1) requested medication used as single agent AND disease has progressed following treatment of relapsed/refractory or progressive disease; OR (2) requested medication is substitute for siltuximab when siltuximab is in shortage or unavailable. Authorization of 12 months may be granted.
Authorization of 12 months may be granted
Immune checkpoint inhibitor-related toxicity (inflammatory arthritis): Moderate or severe immunotherapy-related inflammatory arthritis AND either inadequate response to corticosteroids or a conventional synthetic drug (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine) OR intolerance/contraindication to corticosteroids and a conventional synthetic drug. Authorization of 12 months may be granted; authorization of 6 months may be granted when criteria limited to inadequate response to systemic corticosteroids or intolerance/contraindication to corticosteroids.

Continuation Therapy Criteria

Continuation (Renewal) Criteria

Authorization for continued therapy may be granted when ALL of the following are met (duration typically 6–12 months depending on indication):

Initial criteria: Member meets indication-specific initial authorization criteria (for CRS, acute GVHD, and immune checkpoint inhibitor-related toxicity, continuation requires meeting all initial criteria).
Documentation of response: Chart notes or medical record documentation supporting positive clinical response.
RA-specific response: For RA: improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability.≥ 20% improvement
Articular JIA response: For articular JIA: improvement in number of active joints, limitation of movement, or functional ability (low disease activity).
sJIA response: For sJIA: improvement in joints, functional ability, and systemic features (e.g., fever, rash, lymphadenopathy, hepatomegaly, splenomegaly, serositis).
GCA response: For GCA: improvement in headaches, scalp tenderness, temporal artery signs, constitutional symptoms, jaw/tongue claudication, visual symptoms, PMR symptoms, or limb claudication.
SSc-ILD continuation requirement: For SSc-ILD: continued treatment with Actemra or Tyenne (member must already be receiving treatment).
Castleman disease continuation: For unicentric and multicentric Castleman disease: no evidence of unacceptable toxicity or disease progression on current regimen.

Safety Screening & Concomitant Therapy

Safety Screening — Required for All Indications

Prior to initiation in biologic/targeted-synthetic-naïve members:

TB screening and concomitant biologic prohibition

TB screening: Documented negative tuberculosis (TB) test (TST or IGRA) within 12 months of initiating therapy for persons naïve to biologic or targeted synthetic drugs associated with increased TB risk.Negative TST or IGRA within 12 months
If TB screening positive: If TB screening is positive, further testing to confirm no active disease (e.g., chest x‑ray); do not administer tocilizumab if active TB; if latent TB, TB treatment must be started before initiation.
Concomitant biologic/tsm prohibition: Member cannot use tocilizumab concomitantly with any other biologic drug or targeted synthetic drug.

Rheumatoid arthritis response≥ 20% improvement from baseline in tender joint count, swollen joint count, pain, or disability

TB screening windowNegative TST or IGRA within 12 months prior to initiation for biologic/targeted-synthetic-naïve members

Provider Actions

Prior Authorization

Prior authorization required

Submit prior authorization with chart notes, medical records, and claims history demonstrating the indication-specific criteria, prior therapies tried and response, relevant biomarker or laboratory results, and tuberculosis (TB) screening results (TST or IGRA within 12 months for biologic/targeted-synthetic-naïve members).

Documentation Required

Biomarker and imaging documentation

Provide test results and imaging as applicable: rheumatoid factor (RF) and/or anti-CCP and CRP and/or ESR for rheumatoid arthritis; chest high-resolution computed tomography (HRCT) for systemic sclerosis-associated interstitial lung disease (SSc-ILD); temporal artery biopsy or cross‑sectional imaging or acute‑phase reactant elevation (high ESR and/or high CRP) for giant cell arteritis (GCA).

Prior Authorization

Prescriber specialty requirement

Ensure the prescription is written by or in consultation with the required specialist per indication: rheumatologist for RA, articular JIA, sJIA, GCA, and PMR; rheumatologist or pulmonologist for SSc-ILD; oncologist, hematologist, or rheumatologist for immune checkpoint inhibitor‑related inflammatory arthritis; oncologist or hematologist for CRS, Castleman disease, acute GVHD, and related indications.

Documentation Required

Continuation documentation

For renewals, submit chart notes or medical record documentation showing a positive clinical response per the indication‑specific measures (for example: ≥20% improvement in tender/swollen joint count, pain, or disability for RA; low disease activity or improvement in active joints, movement limitation, or functional ability for articular JIA; improvement in systemic features and joints for sJIA; symptom improvement for GCA; continued treatment documented for SSc‑ILD).

Denial Risk

Concomitant biologic use prohibited

Claims may be denied if tocilizumab is used concomitantly with another biologic drug or a targeted synthetic drug; do not use the requested medication concurrently with other biologic or targeted synthetic agents.

Clinical Evidence & References

Primary evidence sources used to develop this policy include Actemra and listed biosimilar package inserts (Genentech Actemra and biosimilar inserts referenced for 2024–2025), the NCCN Drugs & Biologics Compendium, and specialty guideline literature (e.g., ACR, EULAR, ACR/AFA JIA guidelines and other cited society guidance). FDA labeling and compendial guidance were used to inform coverage criteria, dosing limits, indication-specific requirements, and monitoring recommendations.

Background

This policy covers tocilizumab (Actemra) and the listed biosimilars (Avtozma, Tofidence, Tyenne) for multiple inflammatory, autoimmune, and oncologic-related indications (including FDA‑approved uses and selected compendial indications) when the policy’s approval criteria are satisfied. The policy follows FDA labeling and accepted compendia and guideline guidance for indication-specific criteria, dosing limits, and monitoring. Note: hospitalized management of COVID‑19 is not covered under this outpatient policy and should be managed via the member’s inpatient benefit.

Positive clinical response: Improvement in disease‑specific signs and symptoms as defined in the policy (for RA: ≥ 20% improvement from baseline in tender joint count, swollen joint count, pain, or disability; for articular JIA/sJIA: low disease activity or improvement in active joint counts, limitation of movement, or functional ability; for GCA/PMR: improvement in relevant symptoms and inflammatory markers).